Idiopathic transverse myelitis and neuromyelitis optica: Clinical profiles, pathophysiology and therapeutic choices

Current Neuropharmacology

Volumn 9, Issue 3, 2011, Pages 417-428

  Awad, Amer ^a   Stüve, Olaf ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Epidemiology; Neuromyelitis optica; Pathogenesis; Pathology; References; Transverse myelitis; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; RITUXIMAB;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG MEGADOSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PLASMAPHERESIS;

EID: 79960997776     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911796557948     Document Type: Article

References (174)

1. Jeffery, D.R., Mandler, R.N., Davis, L.E., Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch. Neurol., 1993, 50(5), 532-535.
2. Young, J., Quinn, S., Hurrell, M., Taylor, B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult. Scler., 2009, 15(11), 1295-302.
3. Christensen, P.B., Wermuth, L., Hinge, H.H., Bomers, K., Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol. Scand., 1990, 81(5), 431-435.
4. Krishnan, C., Kaplin, A.I., Deshpande, D.M., Pardo, C.A., Kerr, D.A. Transverse Myelitis: pathogenesis, diagnosis and treatment. Front. Biosci., 2004, 9, 1483-1499.
5. Pidcock, F.S., Krishnan, C., Crawford, T.O., Salorio, C.F., Trovato, M., Kerr, D.A. Acute transverse myelitis in childhood: center- based analysis of 47 cases. Neurology, 2007, 68(18), 1474-1480.
6. Scott, T.F., Bhagavatula, K., Snyder, P.J., Chieffe, C. Transverse myelitis. Comparison with spinal cord presentations of multiple sclerosis. Neurology, 1998, 50(2), 429-433.
7. Paine, R.S., Byers, R.K. Transverse myelopathy in childhood. Am. J. Dis. Child, 1953, 85(2), 151-163.
8. Lipton, H.L., Teasdall, R.D. Acute transverse myelopathy in adults. A follow-up study. Arch. Neurol., 1973, 28(4), 252-257.
9. Ropper, A.H., Poskanzer, D.C. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. Ann. Neurol., 1978, 4(1), 51-59.
10. Dunne, K., Hopkins, I.J., Shield, L.K. Acute transverse myelopathy in childhood. Dev. Med. Child.Neurol., 1986, 28(2), 198-204.
11. Knebusch, M., Strassburg, H.M., Reiners, K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev. Med. Child Neurol., 1998, 40(9), 631-639.
12. de Seze, J., Stojkovic, T., Breteau, G., Lucas, C., Michon-Pasturel, U., Gauvrit, J.Y., Hachulla, E., Mounier-Vehier, F., Pruvo, J.P., Leys, D., Destee, A., Hatron, P.Y., Vermersch, P. Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain, 2001, 124(Pt 8), 1509-1521.
13. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology, 2002, 59(4), 499-505.
14. Miyazawa, R., Ikeuchi, Y., Tomomasa, T., Ushiku, H., Ogawa. T., Morikawa, A. Determinants of prognosis of acute transverse myelitis in children. Pediatr. Int., 2003, 45(5), 512-516.
15. Kalita, J., Misra, U.K., Mandal, S.K. Prognostic predictors of acute transverse myelitis. Acta Neurol. Scand., 1998, 98(1), 60-63.
16. Miller, D.H., McDonald, W.I., Blumhardt, L.D., du Boulay, G.H., Halliday, A.M., Johnson, G., Kendall, B.E., Kingsley, D.P., MacManus, D.G., Moseley, I.F., Rudge P., Sandercock P.A.G. Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann. Neurol., 1987, 22(6), 714-723.
17. Austin, S.G., Zee, C.S., Waters, C. The role of magnetic resonance imaging in acute transverse myelitis. Can. J. Neurol. Sci., 1992, 19(4), 508-511.
18. Tippett, D.S., Fishman, P.S., Panitch, H.S. Relapsing transverse myelitis. Neurology, 1991, 41(5), 703-706.
19. Kesselring, J., Miller, D.H., Robb, S.A., Kendall, B.E., Moseley, I.F., Kingsley, D., du Boulay, E.P., McDonald, W.I. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain, 1990, 113(Pt 2), 291-302.
20. Ravaglia, S., Bastianello, S., Franciotta, D., Ceroni, M., Pichiecchio, A., Tavazzi, E., Moglia, A., Marchioni, E. NMO-IgG- negative relapsing myelitis. Spinal Cord, 2009, 47(7), 531-537.
21. Ungurean, A., Palfi, S., Dibo, G., Tiszlavicz, L., Vecsei, L. Chronic recurrent transverse myelitis or multiple sclerosis. Funct. Neurol., 1996, 11(4), 209-214.
22. Pandit, L., Rao, S. Recurrent myelitis. J. Neurol. Neurosurg. Psychiatry, 1996, 60(3), 336-338.
23. Kim, K.K., Idiopathic recurrent transverse myelitis. Arch. Neurol., 2003, 60(9), 1290-1294.
24. Bakshi, R., Kinkel, P.R., Mechtler, L.L., Bates, V.E., Lindsay, B.D., Esposito, S.E., Kinkel, W.R. Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis. Eur. J. Neurol., 1998, 5(1), 35-48.
25. Bashir, K., Whitaker, J.N. Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult. Scler., 2000, 6(5), 312-316.
26. Ford, B., Tampieri, D., Francis, G. Long-term follow-up of acute partial transverse myelopathy. Neurology, 1992, 42(1), 250-252.
27. Miller, D.H., Ormerod, I.E., Rudge, P., Kendall, B.E., Moseley, I.F., McDonald, W.I., The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. Ann. Neurol., 1989, 26(5), 635-639.
28. Morrissey, S.P., Miller, D.H., Kendall, B.E., Kingsley, D.P., Kelly, M.A., Francis, D.A., MacManus, D.G., McDonald, W.I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain, 1993, 116 (Pt 1), 135-146.
29. Kalita, J., Misra, U.K. Neurophysiological studies in acute transverse myelitis. J. Neurol., 2000, 247(12), 943-948.
30. Misra, U.K., Kalita, J. Can electromyography predict the prognosis of transverse myelitis? J. Neurol., 1998, 245(11), 741-744.
31. Irani, D.N., Kerr, D.A. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet, 2000, 355(9207), 901.
32. Mirich, D.R., Kucharczyk, W., Keller, M.A., Deck, J. Subacute necrotizing myelopathy: MR imaging in four pathologically proved cases. Am. J. Neuroradiol., 1991, 12(6), 1077-1083.
33. Nagaswami, S., Kepes, J., Foster, D.B., Twemlow, S.W., Necrotizing myelitis: a clinico-pathologic report of two cases associated with diplococcus pneumoniae and mycoplasma pneumoniae infections. Trans. Am. Neurol. Assoc., 1973, 98, 290-292.
34. Katz, J.D., Ropper, A.H. Progressive necrotic myelopathy: clinical course in 9 patients. Arch. Neurol., 2000, 57(3), 355-361.
35. Ojeda, V.J., Necrotizing myelopathy associated with malignancy. A clinicopathologic study of two cases and literature review. Cancer, 1984, 53(5), 1115-1123.
36. Van Bogaert, L., Post-infectious encephalomyelitis and multiple sclerosis the significance of perivenous encephalomyelitis. J. Neuropathol. Exp. Neurol., 1950, 9(3), 219-249.
37. Altrocchi, P.H., Acute Transverse Myelopathy. Arch. Neurol., 1963, 9, 111-119.
38. Lerer, R.J., Kalavsky, S.M., Central nervous system disease associated with Mycoplasma pneumoniae infection: report of five cases and review of the literature. Pediatrics, 1973, 52(5), 658-668.
39. Salgado, C.D., Weisse, M.E. Transverse myelitis associated with probable cat-scratch disease in a previously healthy pediatric patient. Clin. Infect. Dis., 2000, 31(2), 609-611.
40. Baig, S.M., Khan, M.A. Cytomegalovirus-associated transverse myelitis in a non-immunocompromised patient. J. Neurol. Sci., 1995, 134(1-2), 210-211.
41. Giobbia, M., Carniato, A., Scotton, P.G., Marchiori, G.C., Vaglia, A. Cytomegalovirus-associated transverse myelitis in a non- immunocompromised patient. Infection, 1999, 27(3), 228-230.
42. Olson, J.K., Eagar, T.N., Miller, S.D. Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J. Immunol., 2002, 169(5), 2719-2726.
43. Williamson, R.A., Burgoon, M.P., Owens, G.P., Ghausi, O., Leclerc, E., Firme, L., Carlson, S., Corboy, J., Parren, P.W., Sanna, P.P., Gilden, D.H., Burton, D. R Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl. Acad. Sci. USA, 2001, 98(4), 1793-1798.
44. Levin, M.C., Lee, S.M., Kalume, F., Morcos, Y., Dohan, F.C, Jr., Hasty, K.A., Callaway, J.C., Zunt, J., Desiderio, D., Stuart, J.M. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat. Med., 2002, 8(5), 509-513.
45. Kappler, J., Kotzin, B., Herron, L., Gelfand, E.W., Bigler, R.D., Boylston, A., Carrel, S., Posnett, D.N., Choi, Y., Marrack, P.V. beta-specific stimulation of human T cells by staphylococcal toxins. Science, 1989, 244(4906), 811-813.
46. Kotzin, B.L., Leung, D.Y., Kappler, J., Marrack, P., Superantigens and their potential role in human disease. Adv. Immunol., 1993, 54, 99-166.
47. Webb, S.R., Gascoigne, N.R. T-cell activation by superantigens. Curr. Opin. Immunol., 1994, 6(3), 467-475.
48. Acha-Orbea, H., MacDonald, H.R. Superantigens of mouse mammary tumor virus. Annu Rev. Immunol., 1995, 13, 459-486.
49. Hong, S.C., Waterbury, G., Janeway CA, Jr. Different super- antigens interact with distinct sites in the Vbeta domain of a single T cell receptor. J. Exp. Med., 1996, 183(4), 1437-1446.
50. Garcia-Merino, A., Blasco, M.R. Recurrent transverse myelitis with unusual long-standing Gd-DTPA enhancement. J. Neurol., 2000, 247(7), 550-551.
51. Kaplin, AI., Deshpande, D.M., Scott, E., Krishnan, C., Carmen, J.S., Shats, I., Martinez, T, Drummond, J., Dike, S., Pletnikov, M., Keswani, S.C., Moran, T.H., Pardo, C.A., Calabresi PA, Kerr DA. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J. Clin. Invest., 2005, 115(10), 2731-2741.
52. Byskosh, P.V., Reder, A.T. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult. Scler., 1996, 1(5), 262-269.
53. Ransohoff, R.M., Howe, C.L., Rodriguez, M. Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends Immunol., 2002, 23(11), 512-516.
54. Gadient, R.A., Otten, U.H. Interleukin-6 (IL-6)--a molecule with both beneficial and destructive potentials. Prog. Neurobiol., 1997, 52(5), 379-390.
55. Kira, J., Kawano, Y., Yamasaki, K., Tobimatsu S. Acute myelitis with hyperIgEaemia and mite antigen specific IgE: atopic myelitis. J. Neurol. Neurosurg. Psychiatry, 1998, 64(5), 676-679.
56. Kikuchi, H., Osoegawa, M., Ochi, H., Murai, H., Horiuchi, I., Takahashi, H., Yamabe, K., Iwaki, T., Mizutani, T., Oda, M., Kira, J., Spinal cord lesions of myelitis with hyperIgEemia and mite antigen specific IgE (atopic myelitis) manifest eosinophilic inflammation. J. Neurol. Sci., 2001, 183(1), 73-88.
57. Defresne, P., Meyer, L., Tardieu, M., Scalais, E., Nuttin, C., De Bont, B., Loftus, G., Landrieu, P., Kadhim, H., Sebire, G. Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J. Neurol. Neurosurg. Psychiatry, 2001, 71(2), 272-274.
58. Kalita, J., Misra, U.K. Is methyl prednisolone useful in acute transverse myelitis? Spinal Cord., 2001, 39(9), 471-476.
59. Sebire, G., Hollenberg, H., Meyer, L., Huault, G., Landrieu, P., Tardieu, M. High dose methylprednisolone in severe acute transverse myelopathy. Arch. Dis. Child, 1997, 76(2), 167-168.
60. Dowling, P.C., Bosch, V.V., Cook, S.D. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology, 1980, 30(7 Pt 2), 33-36.
61. Kennedy, P.G., Weir, A.I. Rapid recovery of acute transverse myelitis treated with steroids. Postgrad. Med. J., 1988, 64(751), 384-385.
62. Lahat, E., Pillar, G., Ravid, S., Barzilai, A., Etzioni, A., Shahar, E. Rapid recovery from transverse myelopathy in children treated with methylprednisolone. Pediatr. Neurol., 1998, 19(4), 279-282.
63. Weinshenker, B.G., O'Brien, P.C., Petterson, T.M., Noseworthy, J.H., Lucchinetti, CF., Dodick D.W., Pineda, A.A., Stevens, L.N., Rodriguez, M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol., 1999, 46(6), 878-886.
64. Weinshenker, B.G., Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J. Clin. Apher., 2001, 16(1), 39-42.
65. Keegan, M., Pineda, A.A., McClelland, R.L., Darby, C.H., Rodriguez, M., Weinshenker, B.G. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology, 2002, 58(1), 143-146.
66. Greenberg, B.M., Thomas, K.P., Krishnan, C., Kaplin, A.I., Calabresi, P.A., Kerr, D.A. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology, 2007, 68(19), 1614-1617.
67. Awad A, Stuve O. Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther. Adv. Neurol. Disord., 2009, 2, 357-368.
68. Kim, Y.H., Choi, B.K., Oh, H.S., Kang, W.J., Mittler, R.S., Kwon, B.S. Mechanisms involved in synergistic anticancer effects of anti- 4-1BB and cyclophosphamide therapy. Mol. Cancer Ther., 2009, 8(2), 469-478.
69. Smith, D.R., Balashov, K.E., Hafler, D.A., Khoury S.J., Weiner H.L., Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann. Neurol, 1997, 42(3), 313-318.
70. Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O., Hartung, H., Seeldrayers, P., Sorensen, P.S., Rovaris, M., Martinelli, V., Hommes, O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, 2001, 357(9268), 1576-1582.
71. Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H.P., Hillert, J., King, J., Komoly, S., Lubetzki, C., Montalban, X., Myhr, K.M., Ravnborg, M., Rieckmann, P., Wynn, D., Young, C., Filippi, M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 374(9700), 1503-1511.
72. O'Connor, P. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin. Ther., 2003, 25(11), 2865-2874.
73. Jacobs, L.D, Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J., Simonian, N A., Slasor, P.J., Sandrock, A.W., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med., 2000, 343(13), 898-904.
74. Siren, A.L., Radyushkin, K., Boretius, S., Kammer, D., Riechers, C.C., Natt, O., Sargin, D., Watanabe, T., Sperling, S., Michaelis, T., Price, J., Meyer, B., Frahm, J., Ehrenreich, H. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain, 2006, 129(Pt 2), 480-489.
75. Xiong, Y., Lu, D., Qu, C., Goussev, A., Schallert, T., Mahmood, A., Chopp, M. Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J. Neurosurg., 2008, 109(3), 510-521.
76. Wingerchuk DM. Neuromyelitis optica: current concepts. Front. Biosci, 2004, 9, 834-840.
77. Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., Pittock, S.J., Weinshenker, B.G. The spectrum of neuromyelitis optica. Lancet Neurol., 2007, 6(9), 805-815.
78. de Seze, J., Lebrun, C., Stojkovic, T., Ferriby, D., Chatel, M., Vermersch, P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult. Scler., 2003, 9(5), 521-525.
79. Mirsattari, S.M., Johnston, J.B., McKenna, R., Del Bigio, M.R., Orr, P., Ross, R.T., Power, C. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology, 2001, 56(3), 317-323.
80. Cabre, P., Heinzlef, O., Merle, H., Buisson, G.G., Bera, O., Bellance, R., Vernant, J.C., Smadja, D. MS and neuromyelitis optica in Martinique (French West Indies). Neurology, 2001, 56(4), 507-514.
81. Osuntokun, B.O. The pattern of neurological illness in tropical Africa. Experience at Ibadan, Nigeria. J. Neurol. Sci., 1971, 12(4), 417-442.
82. Jeffery, A.R., Buncic, J.R. Pediatric Devic's neuromyelitis optica. J. Pediatr. Ophthalmol. Strabismus, 1996, 33(5), 223-229.
83. Lotze, T.E., Northrop, J.L., Hutton, G.J., Ross, B., Schiffman, J.S., Hunter, J.V. Spectrum of pediatric neuromyelitis optica. Pediatrics, 2008, 122(5), e1039-47.
84. Wingerchuk, D.M., Lennon, V.A., Pittock, S.J., Lucchinetti, C.F., Weinshenker, B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology, 2006, 66(10), 1485-1489.
85. Lalive, P.H., Autoantibodies in inflammatory demyelinating diseases of the central nervous system. Swiss Med. Wkly., 2008, 138(47-48), 692-707.
86. Braley, T, Mikol, D.D., Neuromyelitis optica in a mother and daughter. Arch. Neurol., 2007, 64(8), 1189-1192.
87. Yamakawa, K., Kuroda, H., Fujihara, K., Sato, S., Nakashima, I., Takeda, A., Suzuki, K., Itoyama Y. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology, 2000, 55(2), 318-320.
88. Whitham, R.H., Brey, R.L. Neuromyelitis optica: two new cases and review of the literature. J. Clin. Neuroophthalmol., 1985, 5(4), 263-269.
89. Williamson, P.M., Neuromyelitis optica following infectious mononucleosis. Proc. Aust. Assoc. Neurol., 1975, 12, 153-155.
90. Ahasan, H.A., Rafiqueuddin, A.K., Chowdhury, M.A., Azhar, M.A., Kabir, F. Neuromyelitis optica (Devic's disease) following chicken pox. Trop. Doct., 1994, 24(2), 75-76.
91. Keefe, R.J., Neuromyelitis optica with increased intracranial pressure. AMA Arch. Ophthalmol., 1957, 57(1), 110-111.
92. Li W, Minohara, M., Piao, H., Matsushita, T., Masaki, K., Matsuoka, T., Isobe, N., Su, J.J., Ohyagi, Y., Kira, J., Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult. Scler., 2009, 15(12), 1411-1421.
93. Blanche, P., Diaz, E., Gombert, B., Sicard, D., Rivoal, O., Brezin, A. Devic's neuromyelitis optica and HIV-1 infection. J. Neurol. Neurosurg. Psychiatry, 2000, 68(6), 795-796.
94. Silber, M.H., Willcox, P.A., Bowen, R.M., Unger, A. Neuromyelitis optica (Devic's syndrome) and pulmonary tuberculosis. Neurology, 1990, 40(6), 934-938.
95. Wilcox, R.A., Burrow, J., Slee, M., Craig, J., Thyagarajan, D. Neuromyelitis optica (Devic's disease) in a patient with syphilis. Mult. Scler., 2008, 14(2), 268-271.
96. Chusid, M.J., Williamson, S.J., Murphy, J.V., Ramey, L.S. Neuromyelitis optica (Devic disease) following varicella infection. J. Pediatr., 1979, 95(5 Pt 1), 737-738.
97. Ghezzi, A., Bergamaschi, R., Martinelli, V., Trojano, M., Tola, M.R., Merelli, E., Mancardi, L., Gallo, P., Filippi, M., Zaffaroni, M., Comi, G. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J. Neurol., 2004, 251(1), 47-52.
98. Mandler R.N., Davis L.E., Jeffery, D.R., Kornfeld, M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann. Neurol., 1993, 34(2), 162-168.
99. O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry, 1996, 60(4), 382-387.
100. Wingerchuk, D.M., Weinshenker, B.G. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology, 2003, 60(5), 848-853.
101. Wingerchuk, D.M., Hogancamp, W.F., O'Brien, P.C., Weinshenker, B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology, 1999, 53(5), 1107-1114.
102. Misu, T., Fujihara, K., Nakashima, I., Sato, S., Itoyama, Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology, 2005, 65(9), 1479-1482.
103. Al-Araji, A.H., Oger, J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult. Scler., 2005, 11(4), 398-402.
104. Banwell, B., Tenembaum, S., Lennon, V.A., Ursell, E., Kennedy, J., Bar-Or, A., Weinshenker, B.G., Lucchinetti, C.F., Pittock, S.J. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology, 2008, 70(5), 344-352.
105. Bergamaschi, R., Tonietti, S., Franciotta, D., Candeloro, E., Tavazzi, E., Piccolo, G., Romani, A., Cosi, V. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult. Scler., 2004, 10(1), 2-4.
106. Filippi, M., Rocca, M.A., MR imaging of Devic's neuromyelitis optica. Neurol. Sci., 2004, 25(Suppl 4), S371-S373.
107. Pittock, S.J., Weinshenker, B.G., Lucchinetti, C.F., Wingerchuk, D.M., Corboy, J.R., Lennon, V.A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol., 2006, 63(7), 964-968.
108. Vernant, J.C., Cabre, P., Smadja, D., Merle, H., Caubarrere, I., Mikol, J., Poser, C.M. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology, 1997, 48(1), 58-64.
109. Fardet, L., Genereau, T., Mikaeloff, Y., Fontaine, B., Seilhean, D., Cabane, J. Devic's neuromyelitis optica: study of nine cases. Acta Neurol. Scand., 2003, 108(3), 193-200.
110. Rocca, M.A., Agosta, F., Mezzapesa, D.M., Martinelli, V., Salvi, F., Ghezzi, A., Bergamaschi R, Comi, G., Filippi, M. Magnetiza- tion transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology, 2004, 62(3), 476-478.
111. de Seze, J., Blanc, F., Jeanjean, L., Zephir, H., Labauge, P., Bouyon, M., Ballonzoli, L., Castelnovo, G., Fleury, M., Defoort, S., Vermersch, P., Speeg, C. Optical coherence tomography in neuromyelitis optica. Arch. Neurol., 2008, 65(7), 920-923.
112. Green, A.J., Cree, B.A., Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J. Neurol. Neurosurg. Psychiatry, 2009, 80(9), 1002-1005.
113. Naismith, R.T., Tutlam, N.T., Xu, J., Shepherd, J.B., Klawiter, E.C., Song, S.K., Cross A.H., Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology, 2009, 73(1), 46-52.
114. Ratchford, J.N., Quigg, M.E., Conger, A., Frohman, T., Frohman, E., Balcer, L.J., Calabresi, P.A., Kerr D.A., Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology, 2009, 73(4), 302-308.
115. Furukawa, Y., Yoshikawa, H., Yachie, A., Yamada, M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur. J. Neurol., 2006, 13(6), 655-658.
116. Karussis, D., Leker, R.R., Ashkenazi, A., Abramsky, O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann. Neurol., 1998, 44(4), 629-634.
117. Kister, I., Gulati, S., Boz, C., Bergamaschi, R., Piccolo, G., Oger, J., Swerdlow, M.L. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch. Neurol., 2006, 63(6), 851-856.
118. Cree, B.A., Goodin, D.S., Hauser, S.L. Neuromyelitis optica. Semin. Neurol., 2002, 22(2), 105-122.
119. Jacob, S., Zarei, M., Kenton, A., Allroggen, H. Gluten sensitivity and neuromyelitis optica: two case reports. J. Neurol. Neurosurg. Psychiatry, 2005, 76(7), 1028-1030.
120. Jacobi, C., Stingele, K., Kretz, R., Hartmann, M., Storch-Hagenlocher, B., Breitbart, A., Wildemann, B. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus, 2006, 15(2), 107-109.
121. Hummers, L.K., Krishnan, C., Casciola-Rosen, L., Rosen, A., Morris, S., Mahoney, J.A., Kerr, D.A., Wigley, F.M. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology, 2004, 62(1), 147-149.
122. Lennon, V.A., Wingerchuk, D.M., Kryzer, T.J., Pittock, S.J., Lucchinetti, C.F., Fujihara, K., Nakashima, I., Weinshenker, B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, 2004, 364(9451), 2106-2112.
123. Weinshenker, B.G., Wingerchuk, D.M., Vukusic, S., Linbo, L., Pittock, S.J., Lucchinetti, C.F., Lennon, V.A. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol., 2006, 59(3), 566-569.
124. Jarius, S., Paul, F., Franciotta, D., Waters, P., Zipp, F., Hohlfeld, R., Vincent, A., Wildemann, B. Mechanisms of disease: aquaporin- 4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol., 2008, 4(4), 202-214.
125. Nakashima, I., Fujihara, K., Miyazawa, I., Misu, T., Narikawa, K., Nakamura, M., Watanabe, S., Takahashi, T., Nishiyama, S., Shiga, Y., Sato, S., Weinshenker, B.G., Itoyama, Y., Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J. Neurol. Neurosurg., Psychiatry, 2006, 77(9), 1073-1075.
126. McKeon, A., Fryer, J.P., Apiwattanakul, M., Lennon, V.A., Hinson, S.R., Kryzer, T.J., Lucchinetti C.F., Weinshenker, B.G., Wingerchuk, D.M., Shuster, E.A., Pittock, S.J. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch. Neurol., 2009, 66(9), 1134-1138.
127. Agre, P., Kozono, D. Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett., 2003, 555(1), 72-78.
128. Nielsen, S., Nagelhus, E.A., Amiry-Moghaddam, M., Bourque, C., Agre, P., Ottersen, O.P. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci., 1997, 17(1), 171-180.
129. Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman, A.S., Hinson, S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med., 2005, 202(4), 473-477.
130. Weinshenker, B.G. Neuromyelitis optica: what it is and what it might be. Lancet, 2003, 361(9361), 889-890.
131. Matiello, M., Lennon, V.A., Jacob, A., Pittock, S.J., Lucchinetti, C.F., Wingerchuk, D.M., Weinshenker, B.G. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology, 2008, 70(23), 2197-200.
132. Lucchinetti, C.F., Mandler, R.N., McGavern, D., Bruck, W., Gleich, G., Ransohoff, R.M., Trebst, C., Weinshenker, B., Wingerchuk, D., Parisi, J.E., Lassmann, H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain, 2002, 125(Pt 7), 1450-1461.
133. Ortiz de Zarate, J.C., Tamaroff, L., Sica, R.E., Rodriguez, J.A. Neuromyelitis optica versus subacute necrotic myelitis. II. Anatomical study of two cases. J. Neurol. Neurosurg. Psychiatry, 1968, 31(6), 641-645.
134. Lefkowitz, D., Angelo, J.N. Neuromyelitis optica with unusual vascular changes. Arch. Neurol., 1984, 41(10), 1103-1105.
135. Roemer, S.F., Parisi, J.E., Lennon, V.A., Benarroch, E.E., Lassmann, H., Bruck, W., Mandler, R.N., Weinshenker, B.G., Pittock, S.J., Wingerchuk, D.M., Lucchinetti, C.F. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain, 2007, 130(Pt 5), 1194-1205.
136. Penton-Rol, G., Cervantes-Llanos, M., Martinez-Sanchez, G., Cabrera-Gomez, J.A., Valenzuela-Silva, C.M., Ramirez-Nunez, O., Casanova-Orta, M., Robinson-Agramonte, M.A., Lopategui- Cabezas, I., Lopez-Saura, P.A. TNF-alpha and IL-10 downregula- tion and marked oxidative stress in Neuromyelitis Optica. J. Inflamm. (Lond), 2009, 6, 18.
137. Correale, J., Fiol, M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology, 2004, 63(12), 2363-2370.
138. Yamasaki, K., Horiuchi, I., Minohara, M., Osoegawa, M., Kawano, Y., Ohyagi, Y., Yamada, T., Kira, J. Hyperprolactinemia in optico- spinal multiple sclerosis. Intern. Med., 2000, 39(4), 296-299.
139. Kira J., A novel feature disclosed in opticospinal multiple sclerosis in Asians. Intern. Med., 2000, 39(4), 272.
140. Kerr, D.A., Ayetey, H. Immunopathogenesis of acute transverse myelitis. Curr. Opin. Neurol., 2002, 15(3), 339-347.
141. Ferrari, C., Boghen, M., Paracchi, A., Rampini, P., Raiteri, F., Benco, R., Romussi, M., Codecasa, F., Mucci, M., Bianco, M. Thyroid autoimmunity in hyperprolactinaemic disorders. Acta Endocrinol. (Copenh), 1983, 104(1), 35-41.
142. Kramer, C.K., Tourinho, T.F., de Castro, W.P., da Costa, Oliveira, M. Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies. Arch. Med. Res., 2005, 36(1), 54-58.
143. Kira, J., Kanai, T., Nishimura, Y., Yamasaki, K., Matsushita, S., Kawano, Y., Hasuo, K., Tobimatsu, S., Kobayashi, T. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann. Neurol., 1996, 40(4), 569-574.
144. Yamasaki, K., Horiuchi, I., Minohara, M., Kawano, Y., Ohyagi, Y., Yamada, T., Mihara, F., Ito, H., Nishimura, Y., Kira, J. HLA- DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain, 1999, 122 (Pt 9), 1689-1696.
145. Brum, D.G., Barreiram, A.A., dos Santos AC, Kaimen-Maciel DR, Matiello M, Costa RM, Deghaide, N.H., Costa, L.S., Louzada-Junior, P., Diniz, P.R., Comini-Frota, E.R., Mendes-Junior, C.T., Donadi E.A., HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult. Scler., 2010, 16(1), 21-29.
146. Haase, C.G., [Devics neuromyelitis optica. Disease or variants of multiple sclerosis?]. Nervenarzt, 2001, 72(10), 750-754.
147. Sinclair, C., Kirk, J., Herron, B., Fitzgerald, U., McQuaid, S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol., 2007, 113(2), 187-194.
148. Misu, T., Fujihara, K., Nakamura, M., Murakami, K., Endo, M., Konno, H., Itoyama, Y. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J. Exp. Med., 2006, 209(3), 269-275.
149. Eikelenboom, M.J., Killestein, J., Uitdehaag, B.M., Polman, C.H. Opticospinal multiple sclerosis: a pathogenetically distinct form? Mult. Scler., 2004, 10(3), 334-335.
150. Kira, J. Multiple sclerosis in the Japanese population. Lancet Neurol., 2003, 2(2), 117-127.
151. Wingerchuk, D.M., Weinshenker, B.G. Neuromyelitis Optica. Curr. Treat Options Neurol., 2005, 7(3), 173-182.
152. Ruprecht, K., Klinker, E., Dintelmann, T., Rieckmann, P., Gold, R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology, 2004, 63(6), 1081-1083.
153. Nozaki, I., Hamaguchi, T., Komai, K., Yamada, M. Fulminant Devic disease successfully treated by lymphocytapheresis. J. Neurol. Neurosurg. Psychiatry, 2006, 77(9), 1094-1095.
154. Shaw, T., Quan, J., Totoritis, M.C., B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann. Rheum. Dis., 2003, 62(Suppl 2), ii55-ii59.
155. Cree, B.A., Lamb, S, Morgan, K., Chen, A., Waubant, E., Genain, C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005, 64(7), 1270-1272.
156. Jacob, A., Weinshenker, B.G., Violich, I., McLinskey, N., Krupp, L., Fox, R.J., Wingerchuk, D.M., Boggild, M., Constantinescu, C.S., Miller A., De Angelis, T., Matiello, M., Cree, B.A., Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol., 2008, 65(11), 1443-1448.
157. Imamura, H., Tanaka, M., Kitagawa, N., Tahara, M., Oono, M., Tanaka, K., Konishi, T. [Trial of rituximab in three patients with neuromyelitis optica]. Rinsho Shinkeigaku, 2009, 49(8), 457-462.
158. Higashida, J., Wun, T., Schmidt, S., Naguwa, S.M., Tuscano, J.M. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J. Rheumatol., 2005, 32(11), 2109-2115.
159. Mandler, R.N., Ahmed, W., Dencoff, J.E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology, 1998, 51(4), 1219-1220.
160. G.B., The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann. N. Y. Acad. Sci., 1993, 685, 400-407.
161. Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., Napoli, S.Q., Sharma, J., Feichter, J., Bakshi, R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol., 2006, 63(7), 957-963.
162. Fox, E.J. Mechanism of action of mitoxantrone. Neurology, 2004, 63(12 Suppl 6), S15-S18.
163. Johnston, A., Gudjonsson, J.E., Sigmundsdottir, H., Ludviksson, B.R., Valdimarsson, H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin. Immunol., 2005, 114(2), 154-163.
164. Jacob, A., Matiello, M., Weinshenker, B.G., Wingerchuk, D.M., Lucchinetti, C., Shuster, E, Carter, J., Keegan, B.M., Kantarci, O.H., Pittock, S.J. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol., 2009, 66(9), 1128-1133.
165. Ransom, J.T. Mechanism of action of mycophenolate mofetil. Ther. Drug Monit., 1995, 17(6), 681-684.
166. Mok, C.C., To, C.H., Mak, A., Poon, W.L. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J. Rheumatol., 2008, 35(1), 172-174.
167. Bakker, J., Metz, L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can. J. Neurol. Sci., 2004, 31(2), 265-267.
168. Nimmerjahn, F., Ravetch, J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med., 2007, 204(1), 11-15.
169. Siragam, V., Crow, A.R., Brinc, D., Song, S., Freedman, J., Lazarus, A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med., 2006, 12(6), 688-692.
170. Spycher, M., Matozan, K., Minnig, K., Zehnder, R., Miescher, S., Hoefferer, L., Rieben, R. In vitro comparison of the complement- scavenging capacity of different intravenous immunoglobulin preparations. Vox Sang, 2009, 97(4), 348-354.
171. Bayry, J., Thirion, M., Misra, N., Thorenoor, N., Delignat, S., Lacroix-Desmazes, S., Bellon, B., Kaveri, S., Kazatchkine, M.D. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol. Sci., 2003, 24 (Suppl 4), S217-S221.
172. Janke, A.D., Yong, V.W. Impact of IVIg on the interaction between activated T cells and microglia. Neurol. Res., 2006, 28(3), 270-274.
173. Warabi, Y., Matsumoto, Y., Hayashi, H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci., 2007, 252(1), 57-61.
174. Bergamaschi, R., Uggetti, C., Tonietti, S., Egitto, M.G., Cosi, V. A case of relapsing neuromyelitis optica treated with glatiramer acetate. J. Neurol., 2003, 250(3), 359-361.